Acrobiosystems Co

Acrobiosystems Co Net Income

The Net Income of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 165.57 M CNY. In the previous year, Net Income was 123.83 M CNY — a change of 33.70% (higher).

Net Income

165.57 MCNY

YoY

33.70%

Last updated:

In 2025, Acrobiosystems Co's profit amounted to 165.57 M CNY, a 33.70% increase from the 123.83 M CNY profit recorded in the previous year.

The Acrobiosystems Co Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Income
Date
Net Income
Jan 1, 2020
115.88 M CNY
Jan 1, 2021
174.21 M CNY
Jan 1, 2022
203.73 M CNY
Jan 1, 2023
153.59 M CNY
Jan 1, 2024
123.83 M CNY
Jan 1, 2025
165.57 M CNY
Jan 1, 2026 (e)
227.36 M CNY
Jan 1, 2027 (e)
329.34 M CNY
The Acrobiosystems Co Net Income history
YEARNet IncomeYoY
est329.34 MCNY+44.85%
est227.36 MCNY+37.32%
165.57 MCNY+33.70%
123.83 MCNY-19.38%
153.59 MCNY-24.61%
203.73 MCNY+16.94%
174.21 MCNY+50.34%
115.88 MCNY+943.79%
11.10 MCNY-2.11%
11.34 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Revenue

Acrobiosystems Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
246.32 M CNY
139.97 M CNY
115.88 M CNY
Jan 1, 2021
384.99 M CNY
196.31 M CNY
174.21 M CNY
Jan 1, 2022
474.43 M CNY
165.63 M CNY
203.73 M CNY
Jan 1, 2023
543.65 M CNY
132.42 M CNY
153.59 M CNY
Jan 1, 2024
645.02 M CNY
109.32 M CNY
123.83 M CNY
Jan 1, 2025
838.12 M CNY
196.96 M CNY
165.57 M CNY
Jan 1, 2026 (e)
1.08 B CNY
220.21 M CNY
227.36 M CNY
Jan 1, 2027 (e)
1.32 B CNY
301.15 M CNY
329.34 M CNY

Acrobiosystems Co Margins

Acrobiosystems Co stock margins

The Acrobiosystems Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Acrobiosystems Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Acrobiosystems Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
91.91 %
56.83 %
47.05 %
Jan 1, 2021
92.57 %
50.99 %
45.25 %
Jan 1, 2022
92.51 %
34.91 %
42.94 %
Jan 1, 2023
91.26 %
24.36 %
28.25 %
Jan 1, 2024
90.93 %
16.95 %
19.20 %
Jan 1, 2025
91.16 %
23.50 %
19.75 %
Jan 1, 2026 (e)
91.16 %
20.48 %
21.15 %
Jan 1, 2027 (e)
91.16 %
22.75 %
24.88 %

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Net Income Details

Understanding Acrobiosystems Co's Profit Margins

The profit margins of Acrobiosystems Co represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Acrobiosystems Co's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Acrobiosystems Co's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Acrobiosystems Co's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Acrobiosystems Co’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Acrobiosystems Co stock

Net Income of Acrobiosystems Co is 165.57 M CNY in 2025.

Net Income of Acrobiosystems Co changed from 123.83 M CNY to 165.57 M CNY, representing a 33.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Income Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's Acrobiosystems Co historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co